Market Newsdesk

REDWOOD CITY, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Sumo Logic, (Nasdaq: SUMO) the pioneer in continuous intelligence, today announced that it will report financial results for the third quarter of fiscal 2021 ended October 31 after market close on Monday, December 7th, 2020. The company will host a conference call on the same day beginning at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss quarterly financial results and business highlights.

To access the conference call, dial (877) 407-0784 from the United States or (201) 689-8560 internationally and reference the company name and conference title. Following the completion of the call, a replay will be available for approximately two weeks. The replay can be accessed by dialling (844) 512-2921 from the United States or (412) 317-6671 internationally and using the recording passcode 13713250. A live webcast and replay of the conference call can also be accessed from the Sumo Logic Investor Relations website at http://investor.sumologic.com.

About Sumo Logic

Sumo Logic Inc., (Nasdaq: SUMO), is the pioneer in continuous intelligence, a new category of software, which enables organizations of all sizes to address the data challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The Sumo Logic Continuous Intelligence Platform™ automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds. More than 2,100 customers around the world rely on Sumo Logic to build, run, and secure their modern applications and cloud infrastructures. Only Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy. For more information, visit www.sumologic.com.

Sumo Logic is a trademark or registered trademark of Sumo Logic in the United States and in foreign countries. All other company and product names may be trademarks or registered trademarks of their respective owners.

Any information regarding offerings, updates, functionality, or other modifications, including release dates, is subject to change without notice. The development, release, and timing of any offering, update, functionality, or modification described herein remains at the sole discretion of Sumo Logic, and should not be relied upon in making a purchase decision, nor as a representation, warranty, or commitment to deliver specific offerings, updates, functionalities, or modifications in the future.

Investor
Relations Contact

Paul Thomas                                                
Sumo Logic                                                
[email protected]
(650) 214-3847

Media Contact

Melissa Liton                                                
Sumo Logic                                                
[email protected]m                                
(650) 814-3882                                        

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — DoubleVerify (“DV”), a leading software platform for digital media measurement, data and analytics, today announced the results of a new study examining publisher challenges amid COVID-19. For the study, DV’s Publisher Division commissioned a survey of 300 executives in the digital media sector, including digital publishers and supply-side platforms. The survey was conducted online from September 11-18, 2020. 

Nearly half struggle with billing management, delaying payments

As a result of the coronavirus pandemic impacting marketing plans, many advertisers have paused or reduced campaign spend. While publishers are facing revenue pressure, DV found that payments are being delayed due to challenges with billing. In fact, nearly half (47%) of all respondents stated that their organization “lacks the resources to support the billing and reconciliation process across our customers, causing payment times to increase.”

“Closing the books is one of the biggest operational drains for publishers, seriously impacting revenue and cash flow at the worst possible time,” said Steven Woolway, EVP of Business Development, DoubleVerify. “Publishers and advertisers need to work together to streamline pacing and delivery discrepancies, and to reduce billing cycles.” 

Three-quarters say they spend too much time processing data

Data management remains a key operational and revenue hurdle for publishers. Nearly three-quarters (73%) indicated that their organization spends “too much time manually processing inventory performance and revenue data.” Similarly, 80% stated the excessive time spent on data collection and processing “limits our ability to optimize inventory performance and revenue.” 

“Publishers have to pull disparate data from all of these scattered connections, including DSPs, SSPs, and exchanges, then they have to consolidate, organize and normalize that data,” said Woolway. “It’s a cumbersome and repetitive process that takes resources away from more revenue-producing initiatives.” 

Communication is biggest campaign delivery challenge 

While the majority (67%) of respondents rated their organization’s campaign delivery process (the management of developing, running and measuring campaigns) positively, one-third (33%) described it negatively, as either “poor” or “fair.” The greatest campaign delivery challenges cited were “communication and synchronization across internal and external parties” (3.63 average ranking with 1 being the most challenging and 7 the least) and “not enough time to focus on analysis and optimization” (3.83 average ranking). 

“From pre-launch planning to troubleshooting, communication misalignment on campaign delivery can undercut a publisher’s ability to meet the buyer’s goals,” said Pieter Mees, VP Video & Publisher Product, DoubleVerify. “Publishers, advertisers and vendors need to be clear and transparent with one another to satisfy objectives and expectations. Publishers also said they don’t have sufficient time to analyze and optimize campaign delivery, which is critical. This could stem from time spent on onerous, manual activities, like data processing.” 

Publishers cite impression-level fraud as a key threat 

When asked whether real-time inventory quality data (e.g., viewability, brand safety, invalid traffic, etc.) was easily accessible for optimization, 80% of publishers responded that it was. However, there were some challenges – namely “lack of consistent media quality measurement methodologies between advertiser clients” (2.84 average ranking with 1 being the most challenging and 5 the least) and “the ability to proactively identify and troubleshoot impression-level fraud issues” (2.92 average ranking). 

“Different advertisers often use a different combination of solutions to evaluate media quality or performance, impacting a publisher’s ability to make sense of how their inventory is viewed or deliver on goals,” said Mees. “To solve for that, publishers would benefit from better data pipelines and the ability to investigate data discrepancies to streamline their workflows and maximize their media’s performance.”

On the issue of fraud, Mees added, “Ad fraud isn’t just a buyer issue – it also eats into a publisher’s resources and monetization opportunities. Like advertisers do, publishers also benefit from technology to easily identify and act on invalid traffic to prevent fraud in real-time. This helps them prove the value of their inventory to media buyers.” 

In August, DoubleVerify announced its publisher division to spearhead the company’s relationship with the publisher community, and to lead product innovation efforts designed to help publishers maximize revenue yield and reduce friction with buyers. The division features over 60 employees globally developing actionable insights and supporting R&D and engineering, all in service of helping publishers improve transparency, increase efficiency and maximize inventory monetization. DV serves over 110 publishers, including more than half of the top-100 Comscore-ranked web publishers – fortified through the company’s acquisition of Ad-Juster in 2019.

For more information about DV’s publisher division, contact [email protected]. 

About
DoubleVerify

DoubleVerify is a leading software platform for digital media measurement, data and analytics. DV’s mission is to be the definitive source of transparency and data-driven insights into the quality and effectiveness of digital advertising for the world’s largest brands, publishers and digital ad platforms. DV’s technology platform provides advertisers with consistent and unbiased data and analytics that can be used to optimize the quality and return on digital ad investments. Since 2008, DV has helped hundreds of Fortune 500 companies gain the most from their media spend by delivering best in class solutions across the digital advertising ecosystem, helping to build a better industry. Learn more at www.doubleverify.com.

Contact: [email protected] 

ORLANDO, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) — International Keg Rental LLC (“International Keg”), a leading provider of stainless-steel beer keg leasing and rental services, announced today it has completed the acquisition of substantially all of the assets of Global Asset Rental, dba Global Keg Rental, a global provider of beer industry asset rental services and logistics. As part of its acquisition strategy, International Keg will inject new growth capital into the business to finance its continued expansion internationally.

“We have the right foundation and assets at International Keg to continue servicing the existing customer base while adding new offerings to enhance the customer experience and continuing to grow the business into new geographies,” said Thadeus Avvampato, International Keg’s President. “We expect the business relationship between our entities to remain unchanged; you should continue to receive the same, if not better, service and the same process for billing and charges. We also see strong market opportunities around the world, and look forward to executing on our expansion plans.”

As part of this transaction, International Keg has formed a new leadership team of seasoned industry professionals to run the entity, which includes Thadeus Avvampato as President, and Justin Smith as Chief Financial Officer.

Thadeus Avvampato has over 30 years of sales, operations, leadership, revenue generation and employee development experience across the asset rental, real estate and financial service industries.

Justin Smith has over 15 years of experience in both financial and operational leadership roles including as an executive and CFO for multiple private equity-backed firms in various industries with annual revenues up to $1.5B.  

About International Keg

International Keg is a leading provider of stainless-steel beer keg leasing and rental services in over 40 countries around the globe. Visit our website at: www.intlkeg.com

Contact

Mark Folladori

Vice President
+ 1 407 780 1789
[email protected]

SALT LAKE CITY, UT, Nov. 13, 2020 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) (www.sintx.com), an original equipment manufacturer (OEM) of silicon nitride ceramic for medical and non-medical applications, and Iwatani Corporation of America (ICA), a wholly-owned subsidiary of Iwatani Corporation, announced today that they have entered into a joint development agreement.

The goal of this agreement is to incorporate SINTX AP² silicon nitride powder into polymer materials. These materials will become safe and effective surfaces for IT devices such as cases for cell phones and tablets that are touched frequently. SINTX and Iwatani aim to create surfaces that resist bacteria and viruses. The successful development of these products may help prevent and reduce the spread of respiratory diseases like SARS-CoV-2, Influenza A, and H1N1 by inactivating viruses and bacteria on the polymer surfaces.

“We are pleased to enter this joint development agreement with Iwatani, toward developing new products that leverage the intrinsic antipathogenic properties of silicon nitride,” said Dr. Bal. “The collaboration with Iwatani is intended to directly apply our material science expertise toward new product development and revenues, a very significant and exciting move for SINTX.”

SINTX and Iwatani intend to capitalize on recent and promising data demonstrating the potential of SINTX AP²silicon nitride powder to inactivate the SARS-CoV-2 virus that is responsible for the global COVID-19 pandemic. Studies showing the rapid inactivation of SARS-CoV-2 by SINTX’s silicon nitride are the latest in a series of papers showing similar activity of silicon nitride against a variety of bacteria and viral strains. SINTX and Iwatani plan to jointly fund collaborative product development activities in Salt Lake City, Utah, and Japan with the support of external laboratories as well.

SINTX notes they are working diligently to incorporate silicon nitride into several products such as masks and consumer electronic products and other surfaces that will help inactivate respiratory pathogens. The joint development agreement between Iwatani and SINTX will help SINTX advance their materials science, while external partners like Iwatani develop commercial products that can help protect the worldwide community against viral diseases.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, AS9100D certified, and ISO 13485:2016 certified manufacturing facility.

For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, SINTX’s ability to complete its obligations under the agreement; the collaboration with Iwatani may not result in the development of any products; that SINTX has not as yet developed any products with antiviral properties which incorporate the use of silicon nitride; products developed under the joint development agreement may not be effective against the SARS-CoV-2 virus; incorporation of silicon nitride into personal protective equipment may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business Inquiries for SINTX:

SINTX Technologies
801.839.3502
[email protected]

Media Inquiries for SINTX:

Amanda Barry
Associate Director, Content and PR
The Summit Group
[email protected]

Attachment

• SINTX Technologies, Inc.

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today that it has signed an Equipment Purchase Agreement (the “Agreement”) with GEA Lyophil GmbH (“GEA”) to deliver a lab-scale Radiant Energy Vacuum (“REV™”) machine for the demonstration and development of REV™ technology for pharmaceutical applications.

GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave’s technology to pharmaceutical companies as a first step in evaluating the merits of adopting larger-scale capacity.

GEA intends to install the customized lab-scale REV™ machine at its pilot facility in Hürth, Germany

In January 2020, EnWave and GEA announced a Joint Development Agreement, where the companies agreed to work closely to combine GEA’s leading pharmaceutical industry manufacturing capabilities with EnWave’s patented microwave-assisted lyophilization technology. GEA is a global leader in the design, manufacture, and installation of GMP equipment to the pharmaceutical sector, and is working with EnWave to incorporate REV™ technology into its suite of products. EnWave’s pharmaceutical technology allows for a rapid and controlled drying process for sensitive vaccines and biological compounds.

Under the terms of the Joint Development Agreement, GEA will be responsible for the design, manufacture and sale of any large-scale REV™ equipment sold to the pharmaceutical sector, and EnWave shall earn an undisclosed royalty based on the revenue generated.

About
GEA Lyophil GmbH

GEA Lyophil GmbH is part of the GEA group of companies. GEA is one of the largest technology suppliers for food and pharmaceutical processing, and a wide range of other industries. The global group specializes in machinery, plants, as well as process technology and components. GEA provides sustainable solutions for sophisticated production processes in diverse end-user markets and offers a comprehensive service portfolio.

For more information about GEA, please visit www.gea.com.

About EnWave

EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products.

REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV™ technology. The company has signed over thirty royalty-bearing licenses to date. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese^® brand.

EnWave has introduced REV™ as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV™ platforms:

1. nutraREV^® which is a drum-based system that dehydrates organic materials quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; and,
2. quantaREV^® which is a tray-based system used for continuous, high-volume low-temperature drying.

More information about EnWave is available at www.enwave.net.

EnWave Corporation

Mr. Brent Charleton, CFA
President and CEO

For further information:
Brent Charleton, CFA, President and CEO at +1 (778) 378-9616
E-mail: [email protected]       

Dan Henriques, CPA, CA, CFO at +1 (604) 835-5212
E-mail: [email protected]

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management’s expec
tations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All
third-party
claims referred to in this release ar
e not guaranteed to be accurate. All
third-party
references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements
are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor it
s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that 3-year clinical outcomes in a nationwide, randomized, pragmatic clinical trial of atrial fibrillation screening – Mhealth Screening to Prevent Strokes (mSToPS) – will be presented at the 2020 American Heart Association (AHA) Scientific Sessions.

Presentation Details

Title:
3-year Clinical Outcomes in a Nationwide, Randomized, Pragmatic Clinical Trial of Atrial Fibrillation Screening – Mhealth Screening to Prevent Strokes (mSToPS)

Presenter: Steven Steinhubl, MD, Scripps Research Translational Institute

Session: To Screen or Not to Screen, and then What? Studies of Detection and Treatment of AF

Date/Time: Monday, November 16, 2020 at 9:21-9:29 a.m. CT

The above presentation will be available to conference registrants for viewing online at the AHA Scientific Sessions’ Virtual Platform at https://professional.heart.org/es/meetings/scientific-sessions.  

iRhythm Technologies Webcast Information

iRhythm Technologies will host a webcast at 2:00 p.m. PT/5:00 p.m ET on Monday, November 16, 2020 to coincide with the 2020 AHA Scientific Sessions. Investors interested in listening to the webcast may do so by accessing the webcast on the “Investors” section of the company’s website at: www.irhythmtech.com.

About the mSToPS Study

Researchers at the Scripps Translational Science Institute (STSI) conducted the study in partnership with collaborators, Aetna and Janssen Pharmaceuticals. The innovative study design demonstrated that the digital solution enabled by Zio effectively monitored a large and geographically dispersed population of patients who had risk factors for AF. 

The study involved 5,214 eligible Aetna members who were identified through claims data to have risk factors for AF but had not been previously diagnosed. 1,738 individuals were enrolled via a web-based platform to undergo either immediate or delayed active ECG monitoring at home for up to 4 weeks with a Zio XT patch monitor (two-week monitoring periods spaced four months apart). Each monitored participant was matched with two non-monitored participants with a similar CHA2DS2-VASc, a standardized stroke-risk assessment score, to act as controls. 

The study looked at the time to first diagnosis of AF and its clinical consequences for the active monitoring cohort as well as the cohort undergoing usual care.

About iRhythm Technologies, Inc. 
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — Evolve Treatment Centers is excited to announce the addition of Shikha Verma, MD, as Medical Director, Northern California, Melissa E. Vallas, MD, as Medical Director, Southern California, and the launch of our Clinical Advisory Board, which will be led by Bradley Peterson, MD.

Dr. Verma is a board-certified General and Child and Adolescent psychiatrist. She has extensive clinical experience in the management of a wide variety of mental health disorders, including attention-deficit/ hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), other anxiety disorders, substance use disorders, mood disorders, psychotic disorders, trauma, autism spectrum disorder, and intellectual disabilities.

Dr. Verma received her early medical training (Bachelor of Medicine and Bachelor of Surgery, MBBS) at Lady Hardinge Medical College at the University of Delhi in Delhi, India. She completed her residency in Psychiatry at Hennepin-Regions Hospital in Minneapolis, Minnesota, and completed a fellowship in Child and Adolescent Psychiatry at the Medical College of Wisconsin in Milwaukee. She was recognized with a Faculty/Teaching award for 2018-2019 by the Rosalind Franklin University of Medicine and Science.

At Evolve Treatment Centers, Dr. Verma will work exclusively with clients at our Northern California facilities in



Danville



,



Gilroy



,



Lafayette



,



San Jose



,



Walnut Creek



, and


all


virtual programs


.

Dr. Vallas is a board certified General and Child & Adolescent psychiatrist. She has extensive clinical experience in the management of a wide variety of mental health disorders, including mood disorders, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and psychosis. She’s skilled at working with patients who have experienced trauma and supporting families with complex needs. 

Dr. Vallas holds a medical degree (with honors) from Meharry Medical College, in Nashville, Tennessee. She completed her residency at Stanford University Hospital in Palo Alto, California, and a fellowship in Child and Adolescent psychiatry at Lucile Packard Children’s Hospital at Stanford University. She’s a member of the American Academy of Child and Adolescent Psychiatrists and the Northern California Psychiatric Society.

At Evolve Treatment Centers, Dr.


Vallas


will work exclusively with clients at our


Southern


California facilities in



Agoura Hills



,



Calabasas



,



Ojai



,



San Diego



,



Tarzana



, and



Woodland Hills



.

Evolve’s Clinical Advisory Board includes leading behavioral health care professionals with expertise in treating adolescents and their families. The Clinical Advisory Board will work collaboratively with executive clinical leadership to identify, advise, and implement evidence-based practices to ensure safe, patient-centered care and achieve high-quality outcomes.

This group of world-class clinical leaders brings comprehensive behavioral health expertise and will provide guidance to support and shape the excellent clinical programming offered at Evolve.

In his role as Chief Medical Officer, Dr. Brad Peterson will lead the Clinical Advisory Board.

Dr. Peterson is the President of Evolve Psychiatry PC, the Director of the Institute for the Developing Mind at Children’s Hospital Los Angeles, the Vice Chair for Research and Director of Child & Adolescent Psychiatry in the Department of Psychiatry, and a professor at Keck School of Medicine of the University of Southern California.

Dr. Peterson received his bachelor’s degree summa cum laude from Tulane University and earned his medical degree from the University of Wisconsin-Madison. He trained in General Psychiatry at Massachusetts General Hospital and Harvard University, in Child Psychiatry at the Child Study Center of Yale University, and in psychoanalysis at the Western New England Institute of Psychoanalysis. He was a faculty member at the Yale Child Study Center and at Columbia University, where he was the founding Director of MRI Research and the Director of Child & Adolescent Psychiatry. He has authored more than 320 peer-reviewed publications.

In his role as President of Evolve Psychiatry PC, Dr. Peterson will provide clinical oversight, expert guidance, and seasoned leadership to the Evolve Treatment Centers psychiatric team.

“

Evolve Psychiatry is a


group


of world-class adolescent psychiatrists who support Evolve teens and families exclusively


,” says Judy Silvia,


Chief Development Officer of Evolve Treatment.


“


This


team of expert


physic


ians dedicated to


treating our clients


– and our clients


only


–


makes Evolve Treatment Centers unique in the field of adolescent mental health care.


This all-star team is committed to the health, safety, and growth of our teens and families


.


We’re excited to lead the way in adolescent mental health treatment


in California


and set


an example


of


clinical excellence and compassionate care


for the whole country.


”

The addition of Drs. Verma, Vallas, and Peterson will continue to support and elevate the mission of Evolve – to provide excellent and ethical clinical care to adolescents and their families.

Evolve Treatment Centers, accredited by CARF and The Joint Commission, offer the highest caliber of care for teens, 12 to 17 years old, struggling with substance abuse or mental health issues. To learn more about our full continuum of Outpatient (OP), Intensive Outpatient (IOP), Partial Hospitalization (PHP), and Residential Treatment Programs (RTC), visit http://www.evolvetreatment.com or call 1-800-665-GROW.

MEDIA CONTACT:
Judy Sylvia
424-653-9546